$CELC
Celcuity Inc

2022 Q3 Form 10-Q Financial Statement

#000149315222022400 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.022M $1.233M $811.3K
YoY Change 59.88% 115.06% 44.87%
% of Gross Profit
Research & Development $9.622M $8.368M $6.696M
YoY Change 93.96% -35.98% 199.43%
% of Gross Profit
Depreciation & Amortization $53.54K $52.45K $55.99K
YoY Change -15.83% -31.53% -43.0%
% of Gross Profit
Operating Expenses $10.64M $9.601M $7.508M
YoY Change 90.07% -29.63% 168.92%
Operating Profit -$10.64M -$9.601M -$7.508M
YoY Change 90.07% -29.63% 168.92%
Interest Expense $537.7K $455.4K -$426.8K
YoY Change -225.78% 16.43% -1778600.0%
% of Operating Profit
Other Income/Expense, Net -$250.2K -$359.8K $0.00
YoY Change -41.48% -7.6% -100.0%
Pretax Income -$10.89M -$9.961M -$7.934M
YoY Change 80.74% -29.02% 184.22%
Income Tax
% Of Pretax Income
Net Earnings -$10.89M -$9.961M -$7.934M
YoY Change 80.74% -29.02% 184.22%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$0.67 -$0.53
Diluted Earnings Per Share -$729.3K -$667.1K -$531.9K
COMMON SHARES
Basic Shares Outstanding 14.94M shares 14.93M shares 14.92M shares
Diluted Shares Outstanding 14.94M shares 14.93M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.48M $66.91M $78.30M
YoY Change -36.39% 60.69% 124.09%
Cash & Equivalents $57.48M $66.91M $78.30M
Short-Term Investments
Other Short-Term Assets $6.949M $4.957M $955.4K
YoY Change 1412.85% 1072.18% 61.93%
Inventory
Prepaid Expenses $6.578M $4.602M
Receivables
Other Receivables $95.30K
Total Short-Term Assets $64.69M $71.96M $79.44M
YoY Change -29.05% 70.32% 122.44%
LONG-TERM ASSETS
Property, Plant & Equipment $302.0K $238.6K $486.0K
YoY Change -53.9% -42.51% 4.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $597.5K $387.4K $486.0K
YoY Change -8.79% -30.56% -25.58%
TOTAL ASSETS
Total Short-Term Assets $64.69M $71.96M $79.44M
Total Long-Term Assets $597.5K $387.4K $486.0K
Total Assets $65.29M $72.35M $79.93M
YoY Change -28.91% 69.01% 119.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.168M $2.305M $2.139M
YoY Change 81.41% 256.09% 572.28%
Accrued Expenses $3.278M $1.683M $1.406M
YoY Change 206.3% 130.69% 112.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $3.920K $5.380K $5.860K
YoY Change -32.88% -7.72% -41.4%
Total Short-Term Liabilities $6.645M $4.150M $3.551M
YoY Change 135.43% 170.12% 203.35%
LONG-TERM LIABILITIES
Long-Term Debt $15.01M $15.01M $14.82M
YoY Change 4.03% 5.43% 148140.0%
Other Long-Term Liabilities $107.8K $0.00 $15.33K
YoY Change -1.0% -23.35%
Total Long-Term Liabilities $15.12M $15.01M $14.84M
YoY Change 3.99% 5.43% 49364.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.645M $4.150M $3.551M
Total Long-Term Liabilities $15.12M $15.01M $14.84M
Total Liabilities $21.77M $19.16M $18.39M
YoY Change 25.36% 21.47% 1442.13%
SHAREHOLDERS EQUITY
Retained Earnings -$84.72M -$73.82M
YoY Change
Common Stock $14.94K $14.94K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $43.53M $53.19M $61.54M
YoY Change
Total Liabilities & Shareholders Equity $65.29M $72.35M $79.93M
YoY Change -28.91% 69.01% 119.79%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$10.89M -$9.961M -$7.934M
YoY Change 80.74% -29.02% 184.22%
Depreciation, Depletion And Amortization $53.54K $52.45K $55.99K
YoY Change -15.83% -31.53% -43.0%
Cash From Operating Activities -$9.307M -$11.29M -$5.933M
YoY Change 129.87% 48.17% 135.3%
INVESTING ACTIVITIES
Capital Expenditures -$12.10K -$22.98K -$11.64K
YoY Change -13.94% -17.63% -137.64%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$12.10K -$22.98K -$11.64K
YoY Change -13.94% -16.13% -61.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -108.2K -72.51K -46.29K
YoY Change -100.2% -100.51% -100.18%
NET CHANGE
Cash From Operating Activities -9.307M -11.29M -5.933M
Cash From Investing Activities -12.10K -22.98K -11.64K
Cash From Financing Activities -108.2K -72.51K -46.29K
Net Change In Cash -9.427M -11.38M -5.991M
YoY Change -119.35% -269.9% -125.71%
FREE CASH FLOW
Cash From Operating Activities -$9.307M -$11.29M -$5.933M
Capital Expenditures -$12.10K -$22.98K -$11.64K
Free Cash Flow -$9.295M -$11.27M -$5.921M
YoY Change 130.37% 48.41% 131.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001603454
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022Q2 CELC Loss On Sale Of Fixed Assets
LossOnSaleOfFixedAssets
usd
CY2021Q2 CELC Loss On Sale Of Fixed Assets
LossOnSaleOfFixedAssets
usd
CELC Loss On Sale Of Fixed Assets
LossOnSaleOfFixedAssets
usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
CELC Issuance Of Common Stock Licensing Agreement
IssuanceOfCommonStockLicensingAgreement
usd
CELC Loss On Disposition Of Assets
LossOnDispositionOfAssets
usd
CELC Increase Decrease In Payroll Tax Receivables
IncreaseDecreaseInPayrollTaxReceivables
usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CELC Proceeds From Follow On Offering Net Of Underwriting Discounts And Offering Costs
ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts
usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
usd
CELC Gross Proceeds From An Atm Offering
GrossProceedsFromAnAtmOffering
usd
CELC Offering And Registration Statement Costs Included In Accrued Expenses
OfferingAndRegistrationStatementCostsIncludedInAccruedExpenses
usd
us-gaap Stock Issued1
StockIssued1
usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
usd
CY2022Q2 CELC Lessee Operating Lease Liability Amount Representing Services
LesseeOperatingLeaseLiabilityAmountRepresentingServices
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38207
dei Entity Registrant Name
EntityRegistrantName
CELCUITY INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2863566
dei Entity Address Address Line1
EntityAddressAddressLine1
16305 36th Avenue North; Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55446
dei City Area Code
CityAreaCode
(763)
dei Local Phone Number
LocalPhoneNumber
392-0767
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
CELC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14941334 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66910824 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84286381 usd
CY2022Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
22009 usd
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
22009 usd
CY2022Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
332824 usd
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
22144 usd
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
95300 usd
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
298764 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4601874 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
722677 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
71962831 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
85351975 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
238629 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
312444 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
148727 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
241901 usd
CY2022Q2 us-gaap Assets
Assets
72350187 usd
CY2021Q4 us-gaap Assets
Assets
85906320 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2304543 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1507099 usd
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5379 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5850 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
156769 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
189858 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1683305 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
802893 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4149996 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2505700 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2449 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61771 usd
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
15011460 usd
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
14625923 usd
CY2022Q2 us-gaap Liabilities
Liabilities
19161456 usd
CY2021Q4 us-gaap Liabilities
Liabilities
17195843 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14941334 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14941334 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14918887 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14918887 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
14941 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
14919 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126995610 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
124622405 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73821820 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55926847 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
53188731 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
68710477 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72350187 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85906320 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8367687 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13070108 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15064000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15306451 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1233040 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
573360 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2044332 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1128787 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9600727 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
13643468 usd
us-gaap Operating Expenses
OperatingExpenses
17108332 usd
us-gaap Operating Expenses
OperatingExpenses
16435238 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9600727 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13643468 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17108332 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16435238 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
455445 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
391187 usd
us-gaap Interest Expense
InterestExpense
890446 usd
us-gaap Interest Expense
InterestExpense
391210 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
95646 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1803 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
103805 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2191 usd
CELC Loss On Sale Of Fixed Assets
LossOnSaleOfFixedAssets
263 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-359799 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-389384 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-786641 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-389282 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9960526 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14032852 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17894973 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16824520 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9960526 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14032852 usd
us-gaap Net Income Loss
NetIncomeLoss
-17894973 usd
us-gaap Net Income Loss
NetIncomeLoss
-16824520 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7414 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7934447 usd
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14930538 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12610917 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14923900 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11845758 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
68710477 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
756271 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
61539715 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1519459 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80541 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9542 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9960526 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
53188731 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11702270 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
449098 usd
CY2021Q1 CELC Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
11257 usd
CY2021Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
25768493 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38962 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3868 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2791668 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
35174544 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
540317 usd
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
25817 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36859 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
289839 usd
CY2021Q2 CELC Stock Issued During Period Value Issuance Of Common Stock Licensing Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement
5000000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14032852 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
27034524 usd
us-gaap Net Income Loss
NetIncomeLoss
-17894973 usd
us-gaap Net Income Loss
NetIncomeLoss
-16824520 usd
us-gaap Depreciation
Depreciation
108436 usd
us-gaap Depreciation
Depreciation
176597 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2275730 usd
us-gaap Share Based Compensation
ShareBasedCompensation
989415 usd
CELC Issuance Of Common Stock Licensing Agreement
IssuanceOfCommonStockLicensingAgreement
5000000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
179539 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
81571 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
205998 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
93397 usd
CELC Loss On Disposition Of Assets
LossOnDispositionOfAssets
263 usd
CELC Increase Decrease In Payroll Tax Receivables
IncreaseDecreaseInPayrollTaxReceivables
-203464 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3879197 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-37496 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
705145 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
438018 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
875412 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-124940 usd
CELC Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
-1686 usd
CELC Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
-6550 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17222132 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10139253 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34621 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57897 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
500 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34621 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57397 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11257 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16956 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
36859 usd
CELC Proceeds From Employee Stock Purchases
ProceedsFromEmployeeStockPurchases
80541 usd
CELC Proceeds From Employee Stock Purchases
ProceedsFromEmployeeStockPurchases
25817 usd
CELC Proceeds From Follow On Offering Net Of Underwriting Discounts And Offering Costs
ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts
25768493 usd
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
652061 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
14347939 usd
CELC Gross Proceeds From An Atm Offering
GrossProceedsFromAnAtmOffering
38962 usd
CELC Payments For Registration Statement Costs
PaymentsForRegistrationStatementCosts
213381 usd
CELC Payments For Registration Statement Costs
PaymentsForRegistrationStatementCosts
29065 usd
CELC Payments For Finance Leases
PaymentsForFinanceLeases
2920 usd
CELC Payments For Finance Leases
PaymentsForFinanceLeases
2900 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-118804 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40197362 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17375557 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
30000712 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84286381 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11637911 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66910824 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41638623 usd
us-gaap Interest Paid Net
InterestPaidNet
504909 usd
us-gaap Interest Paid Net
InterestPaidNet
216242 usd
CELC Offering And Registration Statement Costs Included In Accounts Payable
OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
100422 usd
CELC Offering And Registration Statement Costs Included In Accounts Payable
OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
96111 usd
CELC Offering And Registration Statement Costs Included In Accrued Expenses
OfferingAndRegistrationStatementCostsIncludedInAccruedExpenses
5000 usd
us-gaap Stock Issued1
StockIssued1
964839 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_z7vwbjgzaH6l" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_znPqJSvOvBFe">Accounting Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zPvVRq9IKg8l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_861_zn6TDuB6znc8">Risks and Uncertainties</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on, the clinical and commercial success of its initial drug product, gedatolisib, the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its drug product, gedatolisib, ability to obtain regulatory approval of its diagnostic tests, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020Q3 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
197211 usd
CY2021Q3 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
193517 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
148727 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
156769 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
156769 usd
CY2022Q2 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
28932 usd
CY2022Q2 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
23628 usd
CY2022Q2 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
5304 usd
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
5379 usd
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5379 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
102119 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
3627 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
68080 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3023 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
170199 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
6650 usd
CY2022Q2 CELC Present Value Discount
PresentValueDiscount
-13430 usd
CY2022Q2 CELC Present Value Discounts
PresentValueDiscounts
-19 usd
CY2022Q2 CELC Lessee Finance Lease Liability Amount Representing Services
LesseeFinanceLeaseLiabilityAmountRepresentingServices
-1252 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
156769 usd
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
5379 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060 pure
CY2022Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y10M24D
CY2022Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.010 pure
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
48647 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
97204 usd
CY2022Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1446 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2893 usd
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
11 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
25 usd
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
20269 usd
us-gaap Variable Lease Cost
VariableLeaseCost
40538 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
70373 usd
us-gaap Lease Cost
LeaseCost
140660 usd
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
70544 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
139429 usd
CY2022Q2 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
11 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
25 usd
CY2022Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1461 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2920 usd
CY2022Q2 CELC Cash Paid For Operating And Finance Leases
CashPaidForOperatingAndFinanceLeases
72016 usd
CELC Cash Paid For Operating And Finance Leases
CashPaidForOperatingAndFinanceLeases
142374 usd
CY2022Q2 us-gaap Contractual Obligation
ContractualObligation
2600000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q2 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Remainder Of Fiscal Year
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear
2192203 usd
CY2022Q2 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Two Year
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear
3142793 usd
CY2022Q2 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Three Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears
2008832 usd
CY2022Q2 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Four Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears
1091593 usd
CY2022Q2 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Five Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears
28373 usd
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8463794 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1519459 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
540317 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2275730 usd
us-gaap Share Based Compensation
ShareBasedCompensation
989415 usd
CY2021Q2 us-gaap Class Of Warrant Or Right Reason For Issuing To Nonemployees
ClassOfWarrantOrRightReasonForIssuingToNonemployees
The Loan Agreement also contains certain events of default, warranties and covenants of the Company. In connection with each funding of the Term Loans, the Company is required to issue Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s stock equal to 2.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) $14.40 per share or (ii) the volume weighted price per share of the Company’s stock for the five-trading day period ending on the last trading day immediately preceding the funding date of the Term C Loan
CY2021Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
26042 shares
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
14.40
us-gaap Debt Instrument Interest Rate Terms
DebtInstrumentInterestRateTerms
The Term Loans will mature on the fifth anniversary of the initial funding date and will bear interest at a rate equal to sum of (a) the greater of (i) Prime Rate (as defined in the Loan Agreement) or (ii) 3.25%, plus (b) 5.70%
CELC Prepayment Fees Percentage Description
PrepaymentFeesPercentageDescription
The Company has the option to prepay the loan at any time following the first anniversary of the loan closing, with tiered prepayment fees ranging from 0 – 2% based on when the prepayment would occur
CY2021Q2 us-gaap Debt Conversion Converted Instrument Rate
DebtConversionConvertedInstrumentRate
0.20 pure
CY2022Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
15000000 usd
CY2022Q2 CELC Payment In Kind Interest Debt
PaymentInKindInterestDebt
506000 usd
CY2022Q2 CELC Notes Payable Final Fee
NotesPayableFinalFee
675000 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
319359 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
850181 usd
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
15011460 usd
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5814750 usd
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7753000 usd
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2613250 usd
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
16181000 usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd

Files In Submission

Name View Source Status
0001493152-22-022400-index-headers.html Edgar Link pending
0001493152-22-022400-index.html Edgar Link pending
0001493152-22-022400.txt Edgar Link pending
0001493152-22-022400-xbrl.zip Edgar Link pending
celc-20220630.xsd Edgar Link pending
ex3-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
celc-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
celc-20220630_lab.xml Edgar Link unprocessable
celc-20220630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
celc-20220630_cal.xml Edgar Link unprocessable